A phase II study of low-dose afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402)

被引：0

作者：

Fujimoto, D. ^{[1
]}

Yokoyama, T. ^{[2
]}

Yoshioka, H. ^{[2
]}

Demura, Y. ^{[3
]}

Hirano, K. ^{[4
]}

Kawai, T. ^{[5
]}

Kagami, R. ^{[6
]}

Ishida, T. ^{[2
]}

Tomii, K. ^{[1
]}

Akai, M. ^{[3
]}

Hirabayashi, M. ^{[4
]}

Nishimura, T. ^{[5
]}

Nakahara, Y. ^{[6
]}

Kim, Y. H. ^{[7
]}

Yoshimura, K. ^{[8
]}

Hirai, T. ^{[7
]}

机构：

[1] Kobe City Med Ctr Gen Hosp, Resp Med, Kobe, Hyogo, Japan

[2] Kurashiki Cent Hosp, Resp Med, Kurashiki, Okayama, Japan

[3] Japanese Red Cross Fukui Hosp, Resp Med, Fukui, Japan

[4] Hyogo Prefectural Amagasaki Gen Med Ctr, Resp Med, Amagasaki, Hyogo, Japan

[5] Kyoto Katsura Hosp, Resp Med, Kyoto, Japan

[6] Natl Hosp Org Himeji Med Ctr, Resp Med, Himeji, Hyogo, Japan

[7] Kyoto Univ Hosp, Resp Med, Kyoto, Japan

[8] Kanazawa Univ, Innovat Clin Res Ctr, Kanazawa, Ishikawa, Japan

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

465P

引用

页数：2